• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday

    6/29/23 8:53:03 AM ET
    $FHTX
    $GDOT
    $GIS
    $INVH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $FHTX alert in real time by email
    • Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ:MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market trading.
    • Credit Suisse cut the price target for Pfizer Inc. (NYSE:PFE) from $47 to $40. Credit Suisse analyst Trung Huynh downgraded the stock from Outperform to Neutral. Pfizer shares fell 0.7% to $36.02 in pre-market trading.
    • Pivotal Research slashed the price target for Liberty Global plc (NASDAQ:LBTYK) from $30 to $25. Pivotal Research analyst Jeffrey Wlodarczak maintained a Buy rating. Liberty Global shares fell 1.3% to close at $17.89 on Wednesday.
    • Keefe, Bruyette & Woods lifted Green Dot Corporation (NYSE:GDOT) price target from $17 to $20. Keefe, Bruyette & Woods analyst Michael Perito maintained the stock with a Market Perform rating. Green Dot shares rose 1.8% to close at $18.61 on Wednesday.
    • Goldman Sachs cut Foghorn Therapeutics Inc. (NASDAQ:FHTX) price target from $21 to $19. Goldman Sachs analyst Paul Choi maintained a Buy rating. Foghorn Therapeutics shares rose 2.4% to close at $8.60 on Wednesday.
    • HC Wainwright & Co. boosted Roivant Sciences Ltd. (NASDAQ:ROIV) price target from $15 to $18. HC Wainwright & Co. analyst Douglas Tsao maintained a Buy rating. Roivant Sciences shares fell 1.2% to $9.95 in pre-market trading.
    • Morgan Stanley raised Schrödinger, Inc. (NYSE:SDGR) price target from $38 to $52. Morgan Stanley analyst Vikram Malhorta maintained an Equal-Weight rating. Schrödinger shares rose 1.9% to $45.64 in pre-market trading.
    • UBS raised the price target for Symbotic Inc. (NASDAQ:SYM) from $34 to $40. UBS analyst Chris Snyder downgraded the stock from Buy to Neutral. Symbotic shares rose 0.4% to $42.00 in pre-market trading.
    • Morgan Stanley lowered General Mills, Inc. (NYSE:GIS) price target from $77 to $72. Morgan Stanley analyst Pamela Kaufman maintained an Underweight rating. General Mills shares fell 0.1% to $76.65 in pre-market trading.
    • B of A Securities boosted The RealReal, Inc. (NASDAQ:REAL) price target from $1 to $1.85. B of A Securities analyst Michael McGovern upgraded the stock from Underperform to Neutral. RealReal shares rose 2.2% to $1.85 in pre-market trading.
    • Keybanc raised Invitation Homes Inc. (NYSE:INVH) price target from $35 to $37. Keybanc analyst Austin Wurschmidt maintained an Overweight rating. Invitation Homes shares rose 0.6% to close at $34.26 on Wednesday.

     

    Check This Out: Uber, ON Semiconductor And 2 Other Stocks Insiders Are Selling

    Get the next $FHTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FHTX
    $GDOT
    $GIS
    $INVH

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Symbotic Inc.
    $SYM
    2/19/2026$70.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Foghorn Therapeutics Inc.
    $FHTX
    2/17/2026$12.00Buy
    Jefferies
    Micron Technology Inc.
    $MU
    2/17/2026$380.00 → $450.00Buy
    Needham
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Micron Technology Inc.
    $MU
    1/23/2026$350.00 → $500.00Buy
    HSBC Securities
    Micron Technology Inc.
    $MU
    1/22/2026Outperform
    William Blair
    Micron Technology Inc.
    $MU
    1/20/2026$300.00 → $450.00Buy
    TD Cowen
    More analyst ratings

    $FHTX
    $GDOT
    $GIS
    $INVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85 and sold $5,298,000 worth of shares (200,000 units at $26.49) (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    2/18/26 5:57:13 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    2/17/26 5:18:05 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manchester Keith S sold $32,658,518 worth of shares (1,225,784 units at $26.64) (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    2/13/26 9:02:15 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $GDOT
    $GIS
    $INVH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $GDOT
    $GIS
    $INVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM

    Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those continuing on daily oral therapy ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced final data from the LATITUDE phase III trial, confirming its long-acting injectable treatment for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of antiretroviral treatment (ART) adherence challenges.1 The 4

    2/18/26 5:00:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Invitation Homes Reports Fourth Quarter and Full Year 2025 Results

    Invitation Homes Inc. (NYSE:INVH) ("Invitation Homes," "we," "our," and "us"), the nation's premier single-family home leasing and management company, today announced our Fourth Quarter ("Q4") 2025 and Full Year ("FY") 2025 financial and operating results. Q4 2025 and FY 2025 Highlights Year over year in Q4 2025, total revenues increased 4.0% to $685 million, total property operating and maintenance costs increased 7.2% to $245 million, and net income available to common stockholders increased 1.0% to $144 million, or $0.24 per diluted common share. In FY 2025, total revenues increased 4.2% to $2,729 million, total property operating and maintenance costs increased 5.4% to $986 million

    2/18/26 4:15:00 PM ET
    $INVH
    Real Estate
    Finance

    $FHTX
    $GDOT
    $GIS
    $INVH
    SEC Filings

    View All

    SEC Form 10-K filed by Invitation Homes Inc.

    10-K - Invitation Homes Inc. (0001687229) (Filer)

    2/19/26 2:47:03 PM ET
    $INVH
    Real Estate
    Finance

    Invitation Homes Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Invitation Homes Inc. (0001687229) (Filer)

    2/18/26 4:11:45 PM ET
    $INVH
    Real Estate
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

    SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    2/13/26 3:32:35 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $GDOT
    $GIS
    $INVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Teyin M bought $7,821,723 worth of shares (23,200 units at $337.14), increasing direct ownership by 856% to 25,910 units (SEC Form 4)

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    1/15/26 7:07:13 PM ET
    $MU
    Semiconductors
    Technology

    CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/18/25 7:28:11 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $GDOT
    $GIS
    $INVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Symbotic upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Symbotic from Sector Weight to Overweight and set a new price target of $70.00

    2/19/26 7:48:50 AM ET
    $SYM
    Industrial Machinery/Components
    Industrials

    Jefferies resumed coverage on Foghorn Therapeutics with a new price target

    Jefferies resumed coverage of Foghorn Therapeutics with a rating of Buy and set a new price target of $12.00

    2/17/26 7:49:23 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $GDOT
    $GIS
    $INVH
    Leadership Updates

    Live Leadership Updates

    View All

    Hasbro Announces Additions to Board of Directors

    Doug Bowser and Carla Vernón to join as newest Board members Today, Hasbro, Inc. (NASDAQ:HAS), a leading games, IP and toy company, announced that Doug Bowser, retired President and Chief Operating Officer of Nintendo of America Inc., and Carla Vernón, Chief Executive Officer of The Honest Company, Inc. have been appointed to Hasbro's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120899535/en/ "We are delighted to have Doug and Carla join our seasoned and dynamic Board of Directors," said Rich Stoddart, Chair of Hasbro's Board of Directors. "Doug and Carla bring extensive leadership experience across co

    1/20/26 8:30:00 AM ET
    $AMZN
    $GIS
    $HAS
    Catalog/Specialty Distribution
    Consumer Discretionary
    Packaged Foods
    Consumer Staples

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Liberty Global Schedules Investor Call for Full-Year 2025 Results

    Liberty Global Ltd. ("Liberty Global" or the "Company") (NASDAQ:LBTYA, LBTYB and LBTYK)) today announced plans to release its full-year 2025 results on the morning of Wednesday, February 18, 2026. You are invited to join in its Investor Call, which will begin at 09:00 a.m. (Eastern Time). During the call, management will discuss the Company's results and may provide other forward-looking information. A listen-only webcast, along with a summary investor presentation, can be found on the Liberty Global website at https://edge.media-server.com/mmc/p/eodb3h93. The webcast will be archived in the Investor Relations section of the Company's website for at least 75 days. ABOUT LIBERTY GLOBAL Li

    11/24/25 4:01:00 PM ET
    $LBTYA
    $LBTYB
    $LBTYK
    Cable & Other Pay Television Services
    Telecommunications

    $FHTX
    $GDOT
    $GIS
    $INVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invitation Homes Inc.

    SC 13G/A - Invitation Homes Inc. (0001687229) (Subject)

    11/14/24 11:25:18 AM ET
    $INVH
    Real Estate
    Finance

    SEC Form SC 13G filed by Schrodinger Inc.

    SC 13G - Schrodinger, Inc. (0001490978) (Subject)

    11/13/24 4:30:25 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $GDOT
    $GIS
    $INVH
    Financials

    Live finance-specific insights

    View All

    Invitation Homes Reports Fourth Quarter and Full Year 2025 Results

    Invitation Homes Inc. (NYSE:INVH) ("Invitation Homes," "we," "our," and "us"), the nation's premier single-family home leasing and management company, today announced our Fourth Quarter ("Q4") 2025 and Full Year ("FY") 2025 financial and operating results. Q4 2025 and FY 2025 Highlights Year over year in Q4 2025, total revenues increased 4.0% to $685 million, total property operating and maintenance costs increased 7.2% to $245 million, and net income available to common stockholders increased 1.0% to $144 million, or $0.24 per diluted common share. In FY 2025, total revenues increased 4.2% to $2,729 million, total property operating and maintenance costs increased 5.4% to $986 million

    2/18/26 4:15:00 PM ET
    $INVH
    Real Estate
    Finance

    General Mills Outlines Progress on Accelerate Strategy at CAGNY Conference

    Company Updates Full-year Fiscal 2026 Outlook Amid Challenging Consumer Environment General Mills, Inc. (NYSE:GIS) will share an update on the company's Accelerate strategy and key initiatives at today's Consumer Analyst Group of New York (CAGNY) Conference. Chairman and Chief Executive Officer Jeff Harmening, Chief Financial Officer Kofi Bruce, and Group President of North America Retail and North America Pet Dana McNabb will outline plans to drive sustainable growth by delivering greater remarkability through the company's global brands. "Since launching our Accelerate strategy six years ago, we've been hard at work transforming General Mills," said Jeff Harmening, chairman and CEO, G

    2/17/26 6:30:00 AM ET
    $GIS
    Packaged Foods
    Consumer Staples

    Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

    Schrödinger, Inc. (NASDAQ:SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed b

    2/11/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care